Stock listing
NYSE:EVMN Evommune, Inc. Stock
Home listing (NYSE) of Evommune, Inc.
Follow Evommune, Inc. into a list and get an email when it puts out news.
Share price · NYSE:EVMN
$7.04 USD +0.16 (+2.3%)
Close on Nov 20, 2026
- Day range
- $6.96 – $7.24 USDNov 20, 2026
- Volume
- 549,397 sharesNov 20, 2026
- Market cap
- $255.5M USDAt the close on Nov 20, 2026 · price × 36.29M shares outstanding
- 52-week range
- $4.94 – $33.20 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $6.76M USDMedian day 594,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:EVMN · Home | $7.04 USD | +0.16 (+2.3%) | 549,397 | $7.10 | $7.24 | $6.96 | $6.88 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:EVMN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.04 | +0.16 | +2.3% | $7.10 | $7.24 | $6.96 | 549,397 | |
| $6.88 | -0.14 | -2.0% | $6.89 | $7.21 | $6.74 | 600,346 | |
| $7.02 | -0.08 | -1.1% | $7.10 | $7.19 | $6.799 | 901,868 | |
| $7.10 | -0.53 | -6.9% | $7.54 | $7.77 | $7.07 | 671,350 | |
| $7.63 | -0.39 | -4.9% | $8.18 | $8.18 | $7.445 | 723,350 | |
| $8.02 | -0.60 | -7.0% | $8.58 | $8.58 | $7.735 | 1,141,350 | |
| $8.62 | +0.78 | +9.9% | $7.90 | $8.92 | $7.79 | 1,432,904 | |
| $7.84 | +0.19 | +2.5% | $7.48 | $8.09 | $7.405 | 843,158 | |
| $7.65 | +1.00 | +15.0% | $6.82 | $7.87 | $6.73 | 823,671 | |
| $6.65 | +0.28 | +4.4% | $6.45 | $6.79 | $6.27 | 455,040 | |
| $6.37 | +0.33 | +5.5% | $6.65 | $7.15 | $6.34 | 1,021,795 | |
| $6.04 | +0.10 | +1.7% | $6.11 | $6.30 | $5.82 | 227,250 | |
| $5.94 | -0.07 | -1.2% | $6.03 | $6.11 | $5.865 | 211,528 | |
| $6.01 | -0.72 | -10.7% | $6.75 | $6.815 | $5.89 | 726,325 | |
| $6.73 | -0.08 | -1.2% | $6.65 | $6.84 | $6.29 | 586,144 | |
| $6.81 | +0.50 | +7.9% | $6.38 | $7.174 | $6.28 | 1,154,441 | |
| $6.31 | +1.15 | +22.3% | $5.50 | $7.21 | $5.35 | 6,509,437 | |
| $5.16 | +0.03 | +0.6% | $5.13 | $5.26 | $4.96 | 1,301,850 | |
| $5.13 | +0.03 | +0.6% | $5.10 | $5.31 | $5.02 | 322,214 | |
| $5.10 | -0.11 | -2.1% | $5.18 | $5.18 | $4.94 | 280,527 | |
| $5.21 | +0.04 | +0.8% | $5.13 | $5.365 | $5.095 | 255,756 | |
| $5.17 | -0.21 | -3.9% | $5.41 | $5.521 | $5.125 | 383,385 | |
| $5.38 | +0.11 | +2.1% | $5.33 | $5.70 | $5.33 | 382,462 | |
| $5.27 | +0.10 | +1.9% | $5.30 | $5.43 | $5.125 | 422,783 | |
| $5.17 | -0.76 | -12.8% | $5.97 | $6.00 | $5.09 | 986,400 | |
| $5.93 | +0.16 | +2.8% | $5.90 | $6.00 | $5.81 | 579,100 | |
| $5.77 | -0.11 | -1.9% | $5.79 | $5.96 | $5.64 | 574,800 | |
| $5.88 | -0.17 | -2.8% | $6.05 | $6.05 | $5.85 | 804,900 | |
| $6.05 | -0.20 | -3.2% | $6.09 | $6.22 | $6.04 | 384,000 | |
| $6.25 | -0.16 | -2.5% | $6.40 | $6.44 | $6.175 | 558,000 | |
| $6.41 | +0.19 | +3.1% | $6.18 | $6.44 | $6.02 | 692,000 | |
| $6.22 | -0.39 | -5.9% | $6.51 | $6.525 | $6.15 | 2,112,500 | |
| $6.61 | -0.04 | -0.6% | $6.67 | $6.67 | $6.08 | 1,007,400 | |
| $6.65 | -0.27 | -3.9% | $6.86 | $7.216 | $6.52 | 1,365,200 | |
| $6.92 | -0.29 | -4.0% | $7.25 | $7.28 | $6.74 | 1,745,400 | |
| $7.21 | -1.05 | -12.7% | $8.25 | $8.30 | $6.99 | 1,524,900 | |
| $8.26 | -0.09 | -1.1% | $8.40 | $8.525 | $8.11 | 720,200 | |
| $8.35 | -0.04 | -0.5% | $8.36 | $8.65 | $8.11 | 807,600 | |
| $8.39 | -0.10 | -1.2% | $8.40 | $8.435 | $8.12 | 660,800 | |
| $8.49 | -0.31 | -3.5% | $8.78 | $8.78 | $8.33 | 541,100 | |
| $8.80 | +0.03 | +0.3% | $8.73 | $8.90 | $8.25 | 992,200 | |
| $8.77 | -0.83 | -8.6% | $9.48 | $9.54 | $8.69 | 872,400 | |
| $9.60 | +0.15 | +1.6% | $9.45 | $9.865 | $9.392 | 573,800 | |
| $9.45 | -0.20 | -2.1% | $9.70 | $9.70 | $9.35 | 603,000 | |
| $9.65 | +0.28 | +3.0% | $9.39 | $9.75 | $9.20 | 1,494,000 | |
| $9.37 | 0.00 | 0.0% | $9.57 | $9.67 | $9.35 | 405,805 | |
| $9.37 | -0.62 | -6.2% | $9.98 | $9.99 | $9.301 | 568,800 | |
| $9.99 | -0.44 | -4.2% | $10.43 | $10.43 | $9.80 | 520,000 | |
| $10.43 | -0.11 | -1.0% | $10.49 | $10.63 | $10.31 | 350,200 | |
| $10.54 | -0.02 | -0.2% | $10.66 | $10.82 | $10.50 | 388,900 | |
| $10.56 | -0.28 | -2.6% | $10.50 | $11.03 | $10.31 | 692,400 | |
| $10.84 | -2.24 | -17.1% | $11.90 | $12.10 | $10.30 | 3,986,300 | |
| $13.08 | +0.81 | +6.6% | $12.11 | $13.35 | $12.01 | 1,235,800 | |
| $12.27 | +0.27 | +2.2% | $11.87 | $12.46 | $11.87 | 249,100 | |
| $12.00 | -0.48 | -3.8% | $12.70 | $12.70 | $11.70 | 594,200 | |
| $12.48 | 0.00 | 0.0% | $12.50 | $12.80 | $12.33 | 366,100 | |
| $12.48 | -0.18 | -1.4% | $12.50 | $12.74 | $12.42 | 278,500 | |
| $12.66 | -0.57 | -4.3% | $13.08 | $13.13 | $12.61 | 571,900 | |
| $13.23 | -0.25 | -1.9% | $13.48 | $13.65 | $12.97 | 350,600 | |
| $13.48 | -0.63 | -4.5% | $14.13 | $14.18 | $13.41 | 252,500 | |
| $14.11 | +0.32 | +2.3% | $14.17 | $14.28 | $13.59 | 342,100 | |
| $13.79 | +0.12 | +0.9% | $13.79 | $14.44 | $13.60 | 340,400 | |
| $13.67 | -0.35 | -2.5% | $13.91 | $13.91 | $13.03 | 228,600 | |
| $14.02 | +0.45 | +3.3% | $13.74 | $14.25 | $13.70 | 326,500 | |
| $13.57 | -1.44 | -9.6% | $14.76 | $14.76 | $13.20 | 764,800 |
- Ticker
- NYSE:EVMN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Latest deck · Nov 12, 2026
Investor Presentation (November 2026)
Investor deck · 61 slides
Latest news
Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Nov 12, 2026
Closed $7.63 (-4.9%) on Nov 13, 2026
Evommune to Present at Upcoming Investor Conferences
Nov 9, 2026
Closed $7.65 (+15.0%) on Nov 9, 2026
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8: 30 a.m. ET
Nov 5, 2026
Closed $6.37 (+5.5%) on Nov 5, 2026
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Oct 1, 2026
Closed $7.21 (-12.7%) on Oct 1, 2026
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Sep 23, 2026
Closed $8.80 (+0.3%) on Sep 24, 2026
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Sep 8, 2026
Closed $10.84 (-17.1%) on Sep 9, 2026
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Aug 6, 2026
Closed $14.08 (+5.2%) on Aug 7, 2026
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Jul 30, 2026
Closed $11.35 (+2.7%) on Jul 30, 2026
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Jun 29, 2026
Closed $15.05 (-40.2%) on Jun 29, 2026
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 7, 2026
Closed $22.92 (+1.9%) on May 8, 2026
Evommune, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 17 in all · newest Nov 12, 2026 · oldest 2025
- Decks
- 12 decks · latest Nov 12, 2026
Where Evommune, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:EVMN · Home listing · This page | NYSE | United States | USD |
| BX Swiss:EVMN | BX Swiss | Switzerland | CHF |
| BOATS:EVMN | BOATS | United States | USD |
| BX Swiss:EVMNUSD | BX Swiss | Switzerland | USD |
Valuation
Price/book 1.0× against a median of 2.0×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $86.86M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.96
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| Ocugen, Inc. · NASDAQ:OCGN | US$260.6M | US$178.1M | n/a | 37.3× | n/a | n/a | n/a | n/a | 1.47 |
| Altimmune, Inc. · NASDAQ:ALT | US$258.8M | US$28.73M | n/a | n/a | n/a | 0.6× | n/a | 0.1× | 1.55 |
| Prelude Therapeutics Incorporated · NASDAQ:PRLD | US$258.6M | US$136.2M | n/a | 6.3× | n/a | 2.1× | −247.1% | 0.1× | 1.48 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.5M | US$243.4M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| TransThera Sciences (Nanjing). Inc. · HKEX:2617 | US$257.1M | US$119.4M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | n/a |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Q32 Bio Inc. · NASDAQ:QTTB | US$249.6M | −US$35.66M | 7.7× | −0.7× | −1.9× | 0.9× | 59.8% | 0.0× | 0.59 |
| Median of the others | US$257.8M | US$128.0M | 7.7× | 6.3× | −1.9× | 2.0× | −144.9% | 0.1× | 1.48 |
Forecasts
5 strong buy · 4 buy · 3 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 22.22 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.39 · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Luis Peña | Executive Director, President & Chief Executive Officer |
| Kyle Carver | Chief Financial Officer |
| Megan Humphreys | Vice President, Corporate Communications |
| Andrea Kim | Vice President, Nonclinical Development |
| J. Mark Jackson | Senior Vice President, Clinical Development |
| Lou Sehl | Senior Vice President, Technical Operations |
| Eugene A. Bauer | Executive Director, Chief Medical Officer |
| Gregory S. Moss | Chief Business and Legal Officer |
| Janice Drew | Chief of Development Operations |
| Jeegar Patel | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Benjamin F. McGraw | Chair of Board |
| Arthur Kirsch | Audit |
| David E. Cohen | Compensation |
| Derek DiRocco | Board Member |
| Eugene A. Bauer | Executive Director, Chief Medical Officer |
| Felice Verduyn-van Weegen | Nominating and Corporate Governance |
| Gregory S. Moss | Chief Business and Legal Officer |
| Jeegar Patel | Chief Scientific Officer |
| Kyle Carver | Chief Financial Officer |
| Luis Peña | Executive Director, President & Chief Executive Officer |
| Rob Hopfner | Audit |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −4.9% |
| Q2 2026 | Aug 6, 2026 · After close | +5.2% |
| Q1 2026 | May 8, 2026 | +3.2% |
| Q4 2025 | Mar 5, 2026 · After close | +5.6% |
| Q3 2025 | Dec 11, 2025 · After close | −8.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 61 slides | Nov 12, 2026 |
| Corporate Update (November 2026) | Corporate update | 20 slides | Nov 4, 2026 |
| Investor Presentation (October 2026) | Investor deck | 47 slides | October 2026 |
| European Academy of Dermatology and Venereology Annual Meeting 2026 | Conference | 10 slides | Oct 1, 2026 |
| Investor Presentation (September 2026) | Investor deck | 39 slides | Sep 15, 2026 |
| Investor Presentation (September 2026) | Investor deck | 42 slides | September 2026 |
| American Headache Society (AHS) Annual Scientific Meeting (June 2026) | Conference | 14 slides | June 2026 |
| Investor Presentation (May 2026) | Investor deck | 62 slides | May 7, 2026 |
| Technical Presentation (April 2026) | Technical | 36 slides | Apr 13, 2026 |
| Investor Presentation (March 2026) | Investor deck | 50 slides | Mar 5, 2026 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (February 2026) | Technical | 27 slides | Feb 10, 2026 |
| Technical Presentation (November 2024) | Technical | 12 slides | Nov 22, 2024 |
Financings
| Raise | Date |
|---|---|
| Private placement of common stock Announced: about US$125M · US$27.88 a share · Morgan Stanley & Co. LLC +5 Dealers: Morgan Stanley & Co. LLC, Leerink Partners LLC, Evercore ISI, Cantor Fitzgerald & Co., William Blair & Company, L.L.C., Oppenheimer & Co. Inc. Use of proceeds: To advance its clinical development programs and for general corporate purposes | Feb 13, 2026 |
| Public offering of common stock Update: US$150M · US$16 a share · Morgan Stanley +3 Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead), Cantor (co-lead) | Nov 6, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Nov 5, 2025.
- Price
- US$16.00 a share
- Shares offered
- 9,375,000 shares of common stock
- Offering size
- US$150 million
- Underwriters' option
- Up to 1,406,250 more shares
- Listing
- EVMN on the New York Stock Exchange
- Underwriters
- MORGAN STANLEY, LEERINK PARTNERS, EVERCORE ISI, CANTOR · In the order on the cover
- Shares delivered
- On or about Nov 7, 2025
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 14, 2025 |
| Filed publicly | Oct 9, 2025 |
| Amended once | Oct 17, 2025 |
| Shares registered with an exchange | Nov 4, 2025 |
| Final prospectus, with the price | Nov 6, 2025 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 6, 2025 |
| FWP · Free writing prospectus | Nov 6, 2025 |
| CERT · Exchange's certificate of listing | Nov 5, 2025 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 4, 2025 |
| FWP · Free writing prospectus | Oct 30, 2025 |
| S-1/A · Registration statement, amended | Oct 17, 2025 |
| S-1 · Registration statement | Oct 9, 2025 |
| DRS/A · Draft registration statement, amended | Sep 23, 2025 |
| DRSLTR · Letter to the SEC with a draft | Sep 22, 2025 |
| UPLOAD · Letter from the SEC | Sep 10, 2025 |
All 17 filings
| Filing | Filed |
|---|---|
| DRS/A · Draft registration statement, amended | Sep 2, 2025 |
| DRSLTR · Letter to the SEC with a draft | Aug 29, 2025 |
| UPLOAD · Letter from the SEC | Jul 30, 2025 |
| DRSLTR · Letter to the SEC with a draft | Jul 18, 2025 |
| DRS/A · Draft registration statement, amended | Jul 18, 2025 |
| UPLOAD · Letter from the SEC | Jun 10, 2025 |
| DRS · Draft registration statement | May 14, 2025 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 6, 2025
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 13.0M | 7.00M | 5.00M |
| Cost of revenue | 1.39M | 1.29M | 1.00M |
| Gross profit | 13.0M | 5.71M | 4.00M |
| Research and development | 74.0M | 64.2M | 32.0M |
| Selling, general and administrative | 20.0M | ||
| Operating income | -81.1M | -70.0M | -37.9M |
| Depreciation and amortization | 600.0K | 500.0K | 1.00M |
| EBITDA | -80.5M | -69.5M | -36.9M |
| Interest expense | 7.00K | 34.0K | 58.0K |
| Income before tax | -68.9M | -68.3M | -34.1M |
| Income tax | 0 | 0 | |
| Net income | -68.9M | -66.8M | -34.1M |
| Earnings per share, basic | -11.22 | -45.29 | -1.13 |
| Earnings per share, diluted | -11.22 | -45.29 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | 44.1M | 16.3M | 29.0M |
| Short-term investments | 105.1M | 55.8M | 50.1M |
| Current assets | 153.5M | 74.0M | 80.0M |
| Property, plant and equipment | 994.0K | 1.33M | |
| Total assets | 224.9M | 76.1M | 82.2M |
| Accounts payable | 7.76M | 8.26M | 1.76M |
| Current liabilities | 17.9M | 28.0M | 6.86M |
| Total debt | 1.71M | 193.3M | 150.6M |
| Total liabilities | 19.4M | 28.5M | 160.0M |
| Shareholders' equity | 205.6M | -144.2M | -77.7M |
| Shares outstanding | 31.5M | 1.55M | 30.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash from operations | -76.4M | -58.2M | -30.0M |
| Capital spending | -235.0K | -88.0K | -118.0K |
| Free cash flow | -76.7M | -58.3M | -30.1M |
| Cash from investing | -115.3M | -3.99M | -48.4M |
| Cash from financing | 220.8M | 49.4M | 63.8M |
| Change in cash | 29.0M | -12.8M | 29.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 17, 2026 | Offer document | SEC |
All 155 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 17, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| 424B3 · Prospectus | Nov 4, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 4, 2026 | Material contract | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 8-K · Current report | Sep 23, 2026 | Current report | SEC |
| 8-K · Current report | Sep 15, 2026 | Current report | SEC |
| 424B3 · Prospectus | Sep 8, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Aug 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 8-K · Current report | Jul 30, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 29, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 29, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 2, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jun 2, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 2, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 424B3 · Prospectus | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 27, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 24, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 22, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 21, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| S-1 · Registration statement | Apr 17, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 13, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 19, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 13, 2026 | Material contract | SEC |
| 8-K · Current report | Feb 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Dec 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Dec 11, 2025 | Results | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 7, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 7, 2025 | Current report | SEC |
| 424B4 · Prospectus | Nov 6, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| FWP · Free writing prospectus | Nov 5, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2025 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Nov 5, 2025 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Nov 4, 2025 | Other filings | SEC |
| FWP · Free writing prospectus | Oct 30, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Oct 17, 2025 | Offer document | SEC |
| S-1 · Registration statement | Oct 9, 2025 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | Sep 22, 2025 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Sep 22, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 10, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Aug 29, 2025 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Aug 29, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 30, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jul 18, 2025 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jul 18, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 10, 2025 | Other filings | SEC |
| DRS · Draft registration statement | May 14, 2025 | Offer document | SEC |
| D | Jan 8, 2025 | Other filings | SEC |
| D | Jan 7, 2025 | Other filings | SEC |
| D | Jan 7, 2025 | Other filings | SEC |
| D | Jan 6, 2025 | Other filings | SEC |
Cap table
Built by 6ix from Evommune, Inc.’s releases · as of Feb 13, 2026
- Common shares
- 36,292,113
- Fully diluted
- 36,292,113
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 36,292,113 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 36,292,113 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Nov 5, 2025 |
| Arthur Kirsch Other companies: Atea Pharmaceuticals, Inc. (Director · Since at least Feb 20, 2025); Liquidia Corporation (Board Member · Since at least Mar 24, 2021); Kadmon Holdings Inc (Director · May 15, 2019 – Nov 9, 2021 · Past); Aralez Pharmaceuticals Inc (Director · May 12, 2016 – Dec 8, 2017 · Past) | Audit · Since at least Nov 5, 2025 |
| Derek DiRocco Other companies: Mineralys Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); Acrivon Therapeutics, Inc. (Director · Since at least May 18, 2026) | Board Member · Since at least Nov 4, 2026 |
| Gregory S. Moss Other companies: Anteris Technologies Global Corp. (Director · Since at least Jun 7, 2025); Kadmon Holdings Inc (EVP, Gen. Coun. / CCO. · Aug 30, 2019 – Nov 9, 2021 · Past) | Chief Business and Legal Officer · Since at least Nov 5, 2025 |
| Benjamin F McGraw III Other companies: Aerie Pharmaceuticals Inc. (Director · Jun 17, 2021 – Nov 21, 2022 · Past) | Director · Since at least Nov 5, 2025 |
| David E. Cohen Other companies: Timber Pharmaceuticals Inc (Director · Apr 15, 2022 – Apr 15, 2023 · Past) | Director · Since at least Nov 5, 2025 |
| Eugene Bauer Other companies: Kadmon Holdings Inc (Director · May 15, 2019 – Nov 9, 2021 · Past) | Executive Director, Chief Medical Officer · Since at least Nov 5, 2025 |
| Andrea Kim | Vice President, Nonclinical Development · Since at least Nov 4, 2026 |
| Benjamin F. McGraw | Chair of Board · Since at least Nov 4, 2026 |
| Felice Verduyn-van Weegen | Nominating and Corporate Governance · Since at least Nov 4, 2026 |
All 18 people
| Person | Seat |
|---|---|
| Janice Drew | Chief of Development Operations · Since at least Jun 24, 2026 |
| Jeegar Patel | Chief Scientific Officer · Since at least Nov 5, 2025 |
| J. Mark Jackson | Senior Vice President, Clinical Development · Since at least Nov 5, 2026 |
| Kyle Carver | Chief Financial Officer · Since at least Nov 5, 2025 |
| Lou Sehl | Senior Vice President, Technical Operations · Since at least Nov 4, 2026 |
| Luis Peña | Executive Director, President & Chief Executive Officer · Since at least Nov 5, 2025 |
| Megan Humphreys | Vice President, Corporate Communications · Since at least Oct 1, 2026 |
| Rob Hopfner | Audit · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Evommune, Inc.